Understanding how Sirtuin 2 helps protect neurons during cancer treatment
The novel role of Sirtuin 2 in regulation of transcription-associated DNA damage repair
['FUNDING_R01'] · UNIV OF ARKANSAS FOR MED SCIS · NIH-11045013
This study is looking at a protein called Sirtuin 2 to see how it might help protect nerve cells from damage caused by cancer treatments like radiation and Cisplatin, with the hope of making life easier for cancer patients who have nerve-related side effects from their therapies.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIV OF ARKANSAS FOR MED SCIS (nih funded) |
| Locations | 1 site (LITTLE ROCK, UNITED STATES) |
| Trial ID | NIH-11045013 on ClinicalTrials.gov |
What this research studies
This research investigates the role of Sirtuin 2, a protein that may help protect nerve cells from damage caused by cancer treatments like radiation and Cisplatin. The study aims to uncover the mechanisms by which Sirtuin 2 contributes to DNA repair in neurons, potentially leading to strategies that reduce neurological side effects while still effectively treating cancer. By focusing on how this protein interacts with DNA repair processes, the research seeks to improve the quality of life for cancer patients who experience neurological deficits from their treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients undergoing treatment with radiation or Cisplatin who are at risk of neurological side effects.
Not a fit: Patients not receiving radiation or Cisplatin as part of their cancer treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that minimize nerve damage during cancer treatment, enhancing patient quality of life.
How similar studies have performed: While the specific role of Sirtuin 2 in this context is novel, similar approaches targeting DNA repair mechanisms have shown promise in other studies.
Where this research is happening
LITTLE ROCK, UNITED STATES
- UNIV OF ARKANSAS FOR MED SCIS — LITTLE ROCK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: XIA, FEN — UNIV OF ARKANSAS FOR MED SCIS
- Study coordinator: XIA, FEN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy, cancer cell, Cancer Patient, cancer therapy